Insider Selling: Masimo Co. (NASDAQ:MASI) COO Sells $5,024,700.00 in Stock

Masimo Co. (NASDAQ:MASI) COO Bilal Muhsin sold 30,000 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $167.49, for a total value of $5,024,700.00. Following the sale, the chief operating officer now owns 24,172 shares in the company, valued at $4,048,568.28. The trade was a 55.38 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Masimo Price Performance

Shares of MASI opened at $168.21 on Friday. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. Masimo Co. has a 1 year low of $101.61 and a 1 year high of $194.88. The stock has a market cap of $9.07 billion, a P/E ratio of 116.01 and a beta of 1.03. The stock’s 50-day moving average price is $174.84 and its two-hundred day moving average price is $157.36.

Masimo (NASDAQ:MASI) last issued its earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.42 by $0.38. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The firm had revenue of $600.70 million for the quarter, compared to analysts’ expectations of $593.35 million. On average, equities analysts predict that Masimo Co. will post 4.1 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Stifel Nicolaus restated a “buy” rating and set a $190.00 target price (up previously from $170.00) on shares of Masimo in a report on Friday, November 22nd. Raymond James raised their price target on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a report on Friday, December 27th. Wells Fargo & Company raised their price target on Masimo from $193.00 to $205.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a report on Wednesday, February 26th. Finally, Piper Sandler raised their price target on Masimo from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Masimo has an average rating of “Moderate Buy” and a consensus price target of $194.80.

Hedge Funds Weigh In On Masimo

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jones Financial Companies Lllp bought a new position in Masimo during the fourth quarter worth about $27,000. UMB Bank n.a. raised its position in shares of Masimo by 180.9% during the fourth quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 123 shares during the period. Trust Co. of Vermont acquired a new stake in shares of Masimo during the fourth quarter worth about $33,000. Blue Trust Inc. raised its position in shares of Masimo by 56.3% during the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 71 shares during the period. Finally, EverSource Wealth Advisors LLC raised its position in shares of Masimo by 40.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 64 shares during the period. Institutional investors own 85.96% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.